Search results
Results from the WOW.Com Content Network
By mid-2014, Accelerator, a biotech investment firm, had raised more than US$30 million from investors, including Eli Lilly and Company, Pfizer, and Johnson & Johnson, for initial funding to create biotechnology startups at the Alexandria Center for Life Science, which encompasses more than 700,000 square feet (65,000 m 2) on East 29th Street ...
Critical Reviews in Biotechnology is an academic journal that publishes comprehensive review articles that organize, evaluate and present the current status of issues ...
Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.It consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein.
A newly minted biopharma initial public offering (IPO) has Wall Street analysts rushing to the gates to price it for massive gains.. Artiva Biotherapeutics (NASDAQ: ARTV) is making waves with its ...
A biologist conducting research in a biotechnology laboratory. Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms and parts thereof for products and services. [1]
Geron Corporation has sponsored human clinical trials of several potential anti-cancer products. Imetelstat (GRN163L) is a drug that targets telomerase. [13] In studies conducted at Johns Hopkins University, GRN163L was active against both CD138+ and CD138neg cancer stem cells and eliminated the colony forming potential of both by five weeks. [14]
Aitia (f.k.a GNS Healthcare) is a biosimulation company based in Somerville, MA. A company called Gene Network Sciences (GNS), was founded in 2000 by Cornell physicists Colin Hill and Iya Khalil, which focused on computational biology models of interactions among genes and proteins in cells, with a focus on cancer drug discovery.
In the United States, a PET scan is estimated to be US$1500-$5000. In England, the National Health Service reference cost (2015–2016) for an adult outpatient PET scan is £798. [93] In Australia, as of July 2018, the Medicare Benefits Schedule Fee for whole body FDG PET ranges from A$953 to A$999, depending on the indication for the scan. [94]